Related Experiment Videos
Reshaping human monoclonal antibodies for imaging and therapy
M E Verhoeyen1, J A Saunders, E L Broderick
1Department of Immunology, Unilever Research, Bedford.
Disease Markers
|May 1, 1991
Summary
Protein engineering overcomes challenges in creating monoclonal antibodies (MoAbs) for medical use. Researchers reshaped human antibodies by grafting rodent binding sites, achieving desired specificities for imaging and therapy.
Area of Science:
- Biotechnology
- Immunology
- Protein Engineering
Background:
- Conventional hybridoma technology faces challenges in producing monoclonal antibodies (MoAbs) suitable for in vivo applications.
- Limitations exist in obtaining MoAbs with desired specificities for therapeutic and imaging purposes.
Purpose of the Study:
- To bypass current problems in monoclonal antibody production using protein engineering.
- To reshape human monoclonal antibodies by grafting rodent antibody binding sites to achieve desired specificities.
Main Methods:
- Utilized protein engineering techniques to modify human antibodies.
- Grafted rodent antibody binding sites onto human acceptor antibodies.
- Developed reshaped human monoclonal antibodies.
Main Results:
- Successfully produced two reshaped human antibodies.
- The reshaped antibodies demonstrated the same specificities as the original mouse antibodies (H17E2 and HMFG1).
- Binding abilities of the reshaped human antibodies were very similar to the original mouse antibodies.
Conclusions:
- Protein engineering offers a viable alternative to hybridoma technology for creating specialized monoclonal antibodies.
- Reshaped human antibodies can serve as effective reagents for in vivo imaging and therapy.
- This technology enables the development of human monoclonal antibodies with tailored specificities and retained binding capabilities.